Lativia - Kilatvia - Pārtikas un veterinārais dienests, Zemkopības ministrija

g kolizejs, sia - 2000g

Lativia - Kilatvia - Pārtikas un veterinārais dienests, Zemkopības ministrija

g kolizejs, sia - pulveris

Lativia - Kilatvia - Pārtikas un veterinārais dienests, Zemkopības ministrija

tasnim e.u. - kapsula

Lativia - Kilatvia - Pārtikas un veterinārais dienests, Zemkopības ministrija

ražots vācijā pēc onesense europe gmbh, hirschstettner strasse 19-21/i, a- 1220, vīne, austrija pasūtījuma - šķidrums

Lativia - Kilatvia - Pārtikas un veterinārais dienests, Zemkopības ministrija

g kolizejs, sia 44103017158 brīvības gatve 439, rīga, lv-1024 - cits, 2000g - cits - diētiskā pārtika, kas paredzēta intensīvas muskuļu piepūles gadījumos, īpaši sportistiem

Lativia - Kilatvia - Pārtikas un veterinārais dienests, Zemkopības ministrija

g kolizejs, sia 44103017158 brīvības gatve 439, rīga, lv-1024 - pulveris - cits - pārtikas produkts, kas paredzēts intensīvas muskuļu piepūles gadījumos, īpaši sportistiem, atbilstoši eiropas parlamenta un padomes 2009.gada 6.maija direktīvas 2009/39/ek par īpašas diētas pārtikas produktiem 1.pielikuma a daļas 5.apakšpunktam

Lativia - Kilatvia - Ecolab

ecolab deutschland gmbh -

Lativia - Kilatvia - Ecolab

ecolab deutschland gmbh -

Lativia - Kilatvia - Ecolab

ecolab deutschland gmbh -

Umoja wa Ulaya - Kilatvia - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiski līdzekļi - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pacienti, kuriem ir ar zemu vai ļoti zemu atkārtošanās risku, nevajadzētu saņemt palīgvielu ārstēšana. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. izņemot tikko diagnosticēta cml hroniskā fāzē, nav kontrolētos pētījumos, kas liecina par klīnisko ieguvumu vai palielina izdzīvošanas šo slimību.